Engineered immune cells take on lupus and scleroderma in first human test
NCT ID NCT06255028
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy faulty B cells that drive the disease. The main goals are to check safety and find the right dose, with only 6 participants enrolled so far.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CNTY-101 (a type of immune cell therapy) with or without IL-2 and chemotherapy
- What this could lead to
- If it works, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to other therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 6 participants, so it's mainly testing safety and dosing. The treatment may not work, and there are risks like cytokine release syndrome and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch
Seattle, Washington, 98109, United States
-
Keck School of Medicine of University of Southern California
Los Angeles, California, 90033, United States
-
Lurie Children's; Northwestern Medicine - Northwestern Medical Group
Chicago, Illinois, 60611, United States
-
Primary Children's Hospital
Salt Lake City, Utah, 84113, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
UC Davis
Sacramento, California, 957817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Can a new pill ease the hardening skin of systemic sclerosis?